<DOC>
	<DOCNO>NCT01190111</DOCNO>
	<brief_summary>This study design evaluate pharmacokinetics 20µg/kg/week Interleukin-7 ( CYT107 ) , biological activity safety repeat cycle CYT107 , maximum 4 cycle within 21 month maximum 3 cycle within 12 month .</brief_summary>
	<brief_title>Study Interleukin-7 ( CYT107 ) HIV Patients</brief_title>
	<detailed_description>This phase IIa study assess weekly dos CYT107 addition antiviral treatment ( HAART ) adult patient HIV . CYT107 administer dose 20 µg/kg base patient 's weight , 3 weekly administration . CYT107 Subcutaneous injection administer clinic day hospital Patients follow every 3 month primary secondary biological activity criterion well safety 24 month long term follow-up quarterly visit . A cycle = 3 weekly administration ; D/d0 ; D/d7 ; D/d14 For patient maximum 3 cycle 12 month maximum 4 cycle 21 month , total duration study 24 month . All patient receive continued receive combination antiretroviral therapy on-study . Pre-medication use systematically might administer need accord standard clinical practice . During study visit follow may do : - Medical history , physical examination , blood test every visit . - Electrocardiogram ( EKG ) - Chest x-ray study - Liver/spleen image - Blood sample collection frequent interval laboratory test ( Virology : HIV RNA &amp; HIV DNA ; Pharmacodynamics/Immunology ; Bacterial translocation ) - Urine test several time study . PBMCs collection immunological test An optional substudy gut biopsy perform prior month 3 first CYT107 cycle evaluate T cell home</detailed_description>
	<criteria>HIV1 infection document licensed ELISA test kit confirm Western Blot time prior study entry . Age ≥18 . On HAART least 12 month , stable regimen least 3 month prior enrollment . HAART define combination 2 class dose regimen approve ARV . CD4 cell count ≥ 101 &lt; 400 cells/mm3 two ( 2 ) consecutive measurement ( include screen value ) within previous 12 month prior enrollment . Plasma HIV RNA &lt; 50 copies/mL least two consecutive measurement ( include screen value ) within previous 6 month prior enrollment . Note : Patients single blip detectable viremia period ( 6 month prior screen ) allow participate prior subsequent plasma HIV RNA level limit detection . No AIDSdefining illness ( category C ) diagnose within last 6 month prior enrollment . Use investigational antiretroviral agent . Any planned probable modification antiretroviral treatment first 3 month study period . Current recent history ( &lt; 30 day prior screen ) viral , bacterial , parasitic fungal infection require systemic treatment and/or hospitalization . Positive PPD unless documentation completion INH therapy latent tuberculosis . Any serious illness require systemic treatment and/or hospitalization patient either complete therapy clinically stable therapy , opinion principal investigator , least 28 day prior study . Any history malignancy ( except basal carcinoma skin ) include hematologic malignancy AIDS defining malignancy , lymphoproliferative disorder Kaposi 's sarcoma . ( Patients Kaposi 's sarcoma limit skin disappear HAART therapy , without require systemic therapy , 1 year prior study entry eligible participate ) . Any history HIV relate encephalopathy . Hepatitis B C ( positive HBs Ag positive anti HBc antibodies detectable HBV DNA viral load positive anti HCV antibodies detectable HCV RNA viral load ) . Patients become negative HBV DNA HCV RNA follow antiviral treatment enrol . HIV2 , HTLV1 HTLV2 seropositivity . Pregnant lactating woman . Women childbearing potential must negative serum urine pregnancy test within 1 week prior study entry . Refusal inability practice contraception regardless gender patient . Hypertension rest systolic blood pressure &gt; 140 rest diastolic blood pressure &gt; 90 mm despite adequate antihypertensive treatment . Use tipranavir/ritonavir ( TPV/r ) Enfuvirtide ( T20 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>interleukin-7</keyword>
	<keyword>immune-based therapy</keyword>
	<keyword>HIV</keyword>
	<keyword>viral disease</keyword>
</DOC>